Overall, these observations strongly suggest that the clinical benefit of targeting SOS1 is not limited to only blocking direct tumor growth, but also to reducing the various clinically deleterious effects of different stromal subpopulations of the TME in LUAD. The gene discussed is SOS1; the disease is neoplasm.